Dashboard
1
Poor Management Efficiency with a low ROCE of 5.82%
- The company has been able to generate a Return on Capital Employed (avg) of 5.82% signifying low profitability per unit of total capital (equity and debt)
2
With a fall in Net Sales of -1.08%, the company declared Very Negative results in Mar 25
3
With ROE of 3.01%, it has a expensive valuation with a 2.44 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,417 Million (Small Cap)
81.00
NA
0.14%
-0.18
3.01%
2.44
Revenue and Profits:
Net Sales:
210 Million
(Quarterly Results - Jun 2025)
Net Profit:
10 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.78%
0%
0.78%
6 Months
-2.05%
0%
-2.05%
1 Year
-1.95%
0%
-1.95%
2 Years
-13.45%
0%
-13.45%
3 Years
-20.86%
0%
-20.86%
4 Years
22.24%
0%
22.24%
5 Years
15.98%
0%
15.98%
Lanzhou Foci Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.21%
EBIT Growth (5y)
36.93%
EBIT to Interest (avg)
76.92
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.20
Sales to Capital Employed (avg)
0.57
Tax Ratio
9.23%
Dividend Payout Ratio
10.20%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.82%
ROE (avg)
5.37%
Valuation key factors
Factor
Value
P/E Ratio
81
Industry P/E
Price to Book Value
2.44
EV to EBIT
138.25
EV to EBITDA
49.22
EV to Capital Employed
2.76
EV to Sales
4.56
PEG Ratio
6.30
Dividend Yield
0.14%
ROCE (Latest)
1.99%
ROE (Latest)
3.01%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
209.90
212.20
-1.08%
Operating Profit (PBDIT) excl Other Income
21.30
32.10
-33.64%
Interest
0.40
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
9.80
20.10
-51.24%
Operating Profit Margin (Excl OI)
33.00%
83.90%
-5.09%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -1.08% vs -20.70% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -51.24% vs -5.19% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
966.10
1,149.80
-15.98%
Operating Profit (PBDIT) excl Other Income
95.50
122.20
-21.85%
Interest
0.90
1.50
-40.00%
Exceptional Items
0.40
-0.00
Consolidate Net Profit
61.70
68.10
-9.40%
Operating Profit Margin (Excl OI)
41.00%
55.00%
-1.40%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -15.98% vs 11.87% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -9.40% vs -37.69% in Dec 2023
About Lanzhou Foci Pharmaceutical Co., Ltd. 
Lanzhou Foci Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






